Results 71 to 80 of about 933,936 (328)

24 | Management of advanced basal cell carcinoma with hedgehog inhibitors: a real-world prospective comparative study

Dermatology Reports
Background: Hedgehog Pathway Inhibitors (HHIs) should be offered to patients with advanced BCC as a first line treatment. Two systemic HHIs are currently available: sonidegib and vismodegib.
Italian Melanoma Intergroup
doaj   +1 more source

Anorectal Melanoma [PDF]

, 2018
Anorectal melanoma (AM) is a rare malignancy, characterized by aggressive behavior and a poor prognosis. AM is more frequent in female patients aged over 50 years.
Dario Didona, Giovanni Paolino, Giulia Macrì, Santo Raffaele Mercuri., Stefano Calvieri   +4 more
core   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

15 | Clinico-pathological features of superficial angiosarcomas: a retrospective study

Dermatology Reports
Background: Angiosarcoma (AS) is a rare malignant vascular neoplasm, classified as either deep or superficial. Among superficial forms, cutaneous angiosarcoma (cAS) and radiation-induced angiosarcoma of the breast (RIAS) are the most frequent.
Italian Melanoma Intergroup
doaj   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

19 | Late draining lymph nodes on preoperative lymphoscintigraphy in melanoma patients: preliminary data from a retrospective study of over 400 cases

Dermatology Reports
Background: Sentinel lymph node biopsy (SLNB) in melanoma allows the identification of patients with clinically non-palpable metastatic lymph nodes. The risk of nodal involvement is related to Breslow thickness, ulceration, or mitotic rate.
Italian Melanoma Intergroup
doaj   +1 more source

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]

, 2014
BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.
Arozarena, Imanol, Erice, O., Ferguson, J., Goicoechea, I., Margison, G.P., Wellbrock, C.   +5 more
core   +2 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

28 | Efficacy and toxicity outcomes with doublet immunotherapy in metastatic melanoma: the real-world REALIPINIVO study

Dermatology Reports
Background: Immunotherapy has significantly improved survival outcomes in metastatic melanoma. Following the Checkmate 067, in January 2022, the Italian Medicines Agency (AIFA) approved combination of Nivolumab+Ipilimumab for the treatment of metastatic
Italian Melanoma Intergroup
doaj   +1 more source

SCD5 restored expression favors differentiation and epithelial-mesenchymal reversion in advanced melanoma [PDF]

, 2018
Our previous data supported a role for the Stearoyl-CoA desaturase (SCD5) in protection against malignancy, whereby it appears to functionally modify tumor stroma impairing tumor spread.
Bellenghi, Maria, Bottero, Lisabianca, Carè, Alessandra, Felicetti, Federica, Gulino, Alessandro, Mattia, Gianfranco, Petrini, Marina, Pontecorvi, Giada, Puglisi, Rossella   +8 more
core   +1 more source